Research programme: staphylokinase-derived thrombolytic agents - Rhein Minapharm

Drug Profile

Research programme: staphylokinase-derived thrombolytic agents - Rhein Minapharm

Alternative Names: Modified SAK; Recombinant staphylokinase variant - Rhein Minapharm Biogenetics; THR-174

Latest Information Update: 04 Feb 2014

Price : $50

At a glance

  • Originator ThromboGenics
  • Developer Rhein Minapharm Biogenetics
  • Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myocardial infarction

Most Recent Events

  • 08 Jan 2014 Preclinical development is ongoing in Egypt
  • 04 Oct 2007 Preclinical trials in Myocardial infarction in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top